Eli Lilly Reports Strong Earnings and Guidance Increase
Eli Lilly (LLY) stock rose 8.7% after the company exceeded earnings and revenue expectations in Q1 2026, driven by its GLP-1 diet drugs. Despite pricing pressures from competition, the company reported a 56% year-over-year revenue increase and 170% profit growth. The company is now shifting focus toward its cancer treatment business.
Tickers: $LLY
Topics: Earnings GLP-1 drugs Profit Growth Revenue Growth Stock Price Movement